UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • R&D pipeline

    The UCB pipeline delivers:

    • a promising portfolio targeting severe diseases and addressing unmet medical needs
    • focus on neurological and immunological diseases
    • more convenient and effective treatments for patients and specialists.

    UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.

    Small molecule drug / NCE

     Neurology

    Antibody-based drug / NBE

     Immunology

     

      Indications Phase 1 Phase 2 Phase 3 Filed
    bimekizumab (IL17AF) psoriasis
      psoriatic arthritis
      axial spondyloarthritis
      hidradenitis suppurativa
    rozanolixizumab (FcRn) myasthenia gravis
      immune thrombocytopenia
      chronic inflammatory demyelinating polyneuropathy (CIDP)
    zilucoplan (C5) myasthenia gravis
      immune-mediated necrotizing myopathy (IMNM)
      amyotrophic lateral sclerosis1
      COVID-associated acute respiratory distress syndrome (ARDS)2
    Staccato® alprazolam active epileptic seizure
    dapirolizumab pegol (CD40L) systemic lupus erythematosus3
    UCB0107 (Tau) progressive supranuclear palsy (PSP)
    1 Project  
    1 Project  

     

    1 In partnership with HEALEY ALS Platform Trial
    2 In partnership with University of Ghent (Belgium) & Medical Research Council (U.K.)
    3 In partnership with Biogen

     

    Information provided on this pages represents molecules currently under investigation and are not approved by any health authority worldwide.

     

    Products
    U.S. Clinical Trials
    U.S. Innovation

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)